Literature DB >> 27240668

[Systemic treatments for psoriasis and psoriatic arthritis].

S Philipp1, G Kokolakis1, R Sabat2,3.   

Abstract

Psoriasis is one of the most common chronic dermatoses. More than 25 % of the affected individuals require effective systemic treatment because of severe symptoms and/or the significantly restricted quality of life. Thanks to intensive research and successful cooperation between academia and the pharmaceutical industry, the options for treating psoriasis have dramatically increased in recent years. Especially targeted therapies give us the opportunity for personalized regimen. This review describes the spectrum of the systemic treatments for psoriasis and psoriatic arthritis and discusses the efficacy, safety, and particular features of the individual substances.

Entities:  

Keywords:  Biologics; Biosimilars; IL-17; Small molecules; TNF

Mesh：

Substances：

Year:  2016        PMID： 27240668     DOI： 10.1007/s00105-016-3812-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  37 in total

1.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors:  Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

2.  PML in a patient treated with fumaric acid.

Authors:  Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

3.  Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.

Authors:  B Bar Oz; R Hackman; T Einarson; G Koren
Journal:  Transplantation       Date:  2001-04-27       Impact factor: 4.939

Review 4.  Combining traditional agents and biologics for the treatment of psoriasis.

Authors:  Jennifer Clay Cather; Alan Menter
Journal:  Semin Cutan Med Surg       Date:  2005-03

5.  German S3-guidelines on the treatment of psoriasis vulgaris (short version).

Authors:  A Nast; W H Boehncke; U Mrowietz; H M Ockenfels; S Philipp; K Reich; T Rosenbach; A Sammain; M Schlaeger; M Sebastian; W Sterry; V Streit; M Augustin; R Erdmann; J Klaus; J Koza; S Müller; H D Orzechowski; S Rosumeck; G Schmid-Ott; T Weberschock; B Rzany
Journal:  Arch Dermatol Res       Date:  2012-02-17       Impact factor: 3.017

6.  Interleukin-29 induces epithelial production of CXCR3A ligands and T-cell infiltration.

Authors:  Ellen Witte; Georgios Kokolakis; Katrin Witte; Katarzyna Warszawska; Markus Friedrich; Demetrios Christou; Stefan Kirsch; Wolfram Sterry; Hans-Dieter Volk; Robert Sabat; Kerstin Wolk
Journal:  J Mol Med (Berl)       Date:  2015-11-26       Impact factor: 4.599

7.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

8.  Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors:  K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

9.  Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Costantino Botsios; Antonio Carletto; Paola Cipriani; Ennio Giulio Favalli; Elena Frati; Valentina Foschi; Stefania Gasparini; AnnaRita Giardina; Elisa Gremese; Florenzo Iannone; Marco Sebastiani; Tamara Ziglioli; Domenico Biasi; Clodoveo Ferri; Mauro Galeazzi; Roberto Gerli; Roberto Giacomelli; Roberto Gorla; Marcello Govoni; Giovanni Lapadula; Antonio Marchesoni; Fausto Salaffi; Leonardo Punzi; Giovanni Triolo; Gianfranco Ferraccioli
Journal:  Autoimmun Rev       Date:  2012-07-13       Impact factor: 9.754

10.  Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.

Authors:  Y Poulin; J J Crowley; R G Langley; K Unnebrink; O M Goldblum; W C Valdecantos
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-06-22       Impact factor: 6.166
View more
  5 in total

1.  [Psoriasis].

Authors:  R Sabat; M P Schön; K Schäkel
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

Review 2.  [Acne inversa/hidradenitis suppurativa: An update].

Authors:  R Sabat; A Tsaousi; J Rossbacher; H Kurzen; T Fadai; U Schwichtenberg; S Schneider-Burrus; G Kokolakis; K Wolk
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

Review 3.  [Drug therapy of acne inversa].

Authors:  S Schneider-Burrus; E Arpa; C Kors; T Stavermann; R Sabat; G Kokolakis
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 4.  [Acne inversa/hidradenitis suppurativa: A challenge for the future].

Authors:  R Sabat
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

5.  Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy.

Authors:  Georgios Kokolakis; Frank Bachmann; Kerstin Wolk; Robert Sabat; Sandra Philipp
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.